Itaiopolis

Researchers are evaluating the safety and preliminary effectiveness of Codivir in 130 hospitalized adults with moderate COVID-19 symptoms. Participants must have symptoms like fever, cough, muscle pain, or changes in smell or taste that started within 7 days before joining. This phase IIa, double-blind, multicenter study involves patients who are hospitalized but medically stable without severe heart or blood flow problems. Participants will receive either Codivir or a placebo alongside standard care. Codivir is given as 20 mg injections under the skin twice daily for 7 days. Treatment starts in the hospital, and if patients improve, they can continue the medication at home with nurse visits twice a day for injections and vital sign checks. If health worsens, patients will remain hospitalized, with doctors deciding on continuing the study drug. Throughout the study, participants will have regular assessments including physical exams, blood tests to check antibodies and virus levels, electrocardiograms, and symptom monitoring. Follow-up calls will be made up to 28 days to track symptoms, side effects, and medication use. The main outcome measured is the change in the World Health Organization clinical improvement scale within 28 days.